222 BERKELEY STREET, BOSTON, MA
Reports Second Quarter 2025 Financial Results and Business Update
News, Underwriting Agreement, Legal Opinion
Positive Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Patients with Acquired Hypothalamic Obesity
Reports First Quarter 2025 Financial Results and Business Update
Annual Report to Security Holders
Investor Presentation
Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement
Other Events
Q2
Q1
FY 2023
Q3
Q2 amended
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership